Table 1 Sample characteristics between the pneumonia and non-pneumonia groups
Variable | Total(n = 383) | Pneumonia Group | Non-Pneumonia Group | P value |
|---|---|---|---|---|
Sex, n (%) | 0.166 | |||
Male | 229(59.8) | 65(54.6) | 164(62.1) | |
Female | 154(40.2) | 54(45.4) | 100(37.9) | |
Age, years, n(%) | < 0.001 | |||
<40 | 135(35.2) | 25(21.0) | 110(41.7) | |
40–49 | 126(32.9) | 40(33.6) | 86(32.6) | |
50–59 | 91(23.8) | 42(35.3) | 49(18.6) | |
≥ 60 | 31(8.1) | 12(10.1) | 19(7.2) | |
BMI ≥ 24 kg/m2, n (%) | 0.316 | |||
No | 290(75.7) | 94(79.0) | 196(74.2) | |
Yes | 93(24.3) | 25(21.0) | 68(25.8) | |
Post-transplantation duration, years, median (IQR) | 4.67(2.42,7.67) | 4.33(1.92,7.25) | 4.79(2.60,8.08) | 0.149 |
Donor type, n (%) | 0.005 | |||
Cadaveric donor | 313(81.7) | 107(89.9) | 206(78.0) | |
Living donor | 70(18.3) | 12(10.1) | 58(22.0) | |
Pre-transplant comorbidities, n (%) | ||||
Cerebrovascular disease | 9(2.3) | 4(3.4) | 5(1.9) | 0.608 |
Myocardial infarct | 5(1.3) | 5(4.2) | 0(0.0) | 0.004 |
Congestive heart failure | 16(4.2) | 6(5.0) | 10(3.8) | 0.770 |
HBV | 27(7.0) | 9(7.6) | 18(6.8) | 0.792 |
Digestive ulcer disease | 10(2.6) | 5(4.2) | 5(1.9) | 0.335 |
Severe anemia | 76(19.8) | 26(21.8) | 50(18.9) | 0.509 |
Tumor | 1(0.3) | 0(0.0) | 1(0.4) | 1.000 |
Tuberculosis | 3(0.8) | 0(0.0) | 3(1.1) | 0.555 |
Immunosuppressive regimen, n (%) | 0.171 | |||
Calcineurin Inhibitors + Mycophenolate Mofetil + Prednisone | 316(82.5) | 102(85.7) | 214(81.1) | |
Calcineurin Inhibitors + Mycophenolate Mofetil | 31(8.1) | 5(4.2) | 26(9.8) | |
Other | 36(9.4) | 12(10.1) | 24(9.1) | |
Post-transplant comorbidities, n (%) | ||||
Cerebrovascular disease | 9(2.3) | 5(4.2) | 4(1.5) | 0.214 |
Transplanted kidney rejection | 15(3.9) | 6(5.0) | 9(3.4) | 0.633 |
Transplanted kidney nephritis or kidney disease | 13(3.4) | 6(5.0) | 7(2.7) | 0.373 |
BK nephropathy | 21(5.5) | 11(9.2) | 10(3.8) | 0.030 |
Pulmonary infection history | 59(15.4) | 44(37.0) | 15(5.7) | < 0.001 |
Tuberculosis | 3(0.8%) | 0(0.0) | 3(1.1) | 0.555 |
Tumour | 5(1.3) | 3(2.5) | 2(0.8) | 0.357 |
PTDM | 68(17.8) | 27(22.7) | 41(15.5) | 0.090 |
Hypertension | 34(8.9) | 11(9.2) | 23(8.7) | 0.866 |
Other | 28(7.3) | 7(5.9) | 21(8.0) | 0.471 |
COVID-19 vaccination status, n (%) | 0.703 | |||
No | 271(70.8) | 86(72.3) | 185(70.1) | |
1 dose | 27(7.0) | 9(7.6) | 18(6.8) | |
2 doses | 32(8.4) | 7(5.9) | 25(9.5) | |
3–4 doses | 53(13.8) | 17(14.3) | 36(13.6) | |
Preventive measures, n (%) | ||||
No | 20(5.2) | 5(4.2) | 15(5.7) | 0.547 |
Bailing Capsules | 26(6.8) | 12(10.1) | 14(5.3) | 0.085 |
ursodeoxycholic | 26(6.8) | 10(8.4) | 16(6.1) | 0.399 |
Personal protection (e.g., wear face mask) | 349(91.1) | 110(92.4) | 239(90.5) | 0.544 |
Other | 4(1.0) | 0(0.0) | 4(1.5) | 0.420 |
Pre-infection eGFR, mL / min / 1.73 m2, mean (SD) | 62.91 ± 23.35 | 53.78 ± 21.26 | 67.02 ± 23.12 | < 0.001 |
Pre-transplant CCI, mean (SD) | 1.95 ± 1.17 | 2.13 ± 1.22 | 1.88 ± 0.14 | 0.051 |
Post-transplant CCI, mean (SD) | 0.53 ± 0.72 | 0.93 ± 0.82 | 0.35 ± 0.58 | < 0.001 |